[Ten questions about hormone replacement therapy and cardiovascular risk].

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Vered Gil Ad, Stefania Angela Di Fusco, Maria Teresa Manes, Beatrice Scardovi, Daniela Pavan, Ivana Pariggiano, Massimo Iacoviello, Ilaria Battistoni, Manuela Benvenuto, Daniele Masarone, Alessandro Maloberti, Pier Luigi Temporelli, Roberta Rossini, Simona Giubilato, Italo Porto, Michela Pittaluga, Massimo Grimaldi, Giovanna Geraci, Furio Colivicchi, Fabrizio Oliva
{"title":"[Ten questions about hormone replacement therapy and cardiovascular risk].","authors":"Vered Gil Ad, Stefania Angela Di Fusco, Maria Teresa Manes, Beatrice Scardovi, Daniela Pavan, Ivana Pariggiano, Massimo Iacoviello, Ilaria Battistoni, Manuela Benvenuto, Daniele Masarone, Alessandro Maloberti, Pier Luigi Temporelli, Roberta Rossini, Simona Giubilato, Italo Porto, Michela Pittaluga, Massimo Grimaldi, Giovanna Geraci, Furio Colivicchi, Fabrizio Oliva","doi":"10.1714/4454.44482","DOIUrl":null,"url":null,"abstract":"<p><p>The impact of hormone replacement therapy (HRT) on the cardiovascular (CV) system in menopausal women has been the subject of significant debate for many years. After a phase marked by restrictive use following the outcomes of the first randomized trials in the 2000s, the last decade has witnessed a significant reassessment of the risks and benefits of therapy, especially CV risk. Thanks to new studies conducted in more selected populations and sub-analyses of earlier trials, there is now ample evidence regarding the high safety profile of HRT, and even protection on the CV system, for young women with a low CV risk profile in the early menopausal phase. This evidence has been incorporated into all national and international menopausal guidelines and, recently, also in a consensus document by the European Society of Cardiology. Therefore, the cardiologist assumes a central role in the risk assessment and treatment of modifiable CV risk factors during the menopausal transition, a critical period for women as it is associated with significant changes in the glycometabolic balance. This article summarises current knowledge on the subject and provides practical guidance for the cardiological management of such patients.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"26 3","pages":"147-158"},"PeriodicalIF":0.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1714/4454.44482","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

The impact of hormone replacement therapy (HRT) on the cardiovascular (CV) system in menopausal women has been the subject of significant debate for many years. After a phase marked by restrictive use following the outcomes of the first randomized trials in the 2000s, the last decade has witnessed a significant reassessment of the risks and benefits of therapy, especially CV risk. Thanks to new studies conducted in more selected populations and sub-analyses of earlier trials, there is now ample evidence regarding the high safety profile of HRT, and even protection on the CV system, for young women with a low CV risk profile in the early menopausal phase. This evidence has been incorporated into all national and international menopausal guidelines and, recently, also in a consensus document by the European Society of Cardiology. Therefore, the cardiologist assumes a central role in the risk assessment and treatment of modifiable CV risk factors during the menopausal transition, a critical period for women as it is associated with significant changes in the glycometabolic balance. This article summarises current knowledge on the subject and provides practical guidance for the cardiological management of such patients.

[关于激素替代疗法和心血管风险的十个问题]。
激素替代疗法(HRT)对绝经期妇女心血管(CV)系统的影响多年来一直是争论不休的主题。在2000年代首次随机试验的结果之后,经过了一个以限制使用为标志的阶段,过去十年见证了对治疗风险和益处的重大重新评估,特别是心血管风险。由于在更多选定人群中进行的新研究和对早期试验的亚分析,现在有充分的证据表明,对于绝经早期CV风险较低的年轻女性,HRT具有高安全性,甚至对CV系统具有保护作用。这一证据已被纳入所有国家和国际更年期指南,最近也被纳入欧洲心脏病学会的共识文件。因此,心脏病专家在绝经过渡期可变心血管危险因素的风险评估和治疗中发挥核心作用,绝经期是妇女的关键时期,因为它与糖代谢平衡的显著变化有关。本文总结了目前关于这一主题的知识,并为这类患者的心脏病管理提供了实用的指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Giornale italiano di cardiologia
Giornale italiano di cardiologia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信